Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
103.36
-3.26 (-3.06%)
Sep 2, 2026, 11:03 AM EDT - Market open

Dianthus Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
5,7811,767645154--
Market Cap Growth
662.03%173.85%318.69%---
Enterprise Value
4,5921,213364-35--
Last Close Price
106.6241.2121.8010.40--

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
3129.86867.84103.4854.53--
PB Ratio
4.993.581.830.91--
P/TBV Ratio
5.083.581.830.91--

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
2505.30595.6458.45---

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.000.000.000.000.01-
Net Debt / Equity Ratio
-1.01-1.04-1.01-1.02-1.01-1.86
Net Debt / EBITDA Ratio
5.462.893.493.602.52-
Net Debt / FCF Ratio
7.643.974.544.682.560.77
Asset Turnover
0.000.000.020.020.14-
Quick Ratio
25.7913.1614.9618.099.861.70
Current Ratio
26.1013.3215.2218.439.971.75
Return on Equity (ROE)
-26.06%-38.38%-32.60%-35.92%-73.25%-
Return on Assets (ROA)
-17.69%-24.58%-23.01%-22.94%-40.12%-
Return on Capital Employed (ROCE)
-18.50%-35.60%-28.60%-28.40%-39.70%-319.20%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-3.23%-9.19%-13.17%-28.26%--
FCF Yield
-2.61%-7.32%-12.13%-23.99%--
Buyback Yield / Dilution
-32.34%-15.92%-546.44%-489.48%78.17%-
SEC Filings: 10-K · 10-Q